Beta Drugs Ltd — 360° view

Beta Drugs Ltd, a company in the Pharmaceuticals industry, reported revenue of ₹137 crore and net profit of ₹19 crore for the September 2026 quarter.

Beta Drugs Ltd (NSE: BETA) closed at ₹1,655.40 on 20 Nov 2026, up 1.4% over the past year. Its market capitalisation is ₹1,841 crore and it trades at 35.5 times earnings.

Share price
₹1,655.40 (20 Nov 2026)
Market cap
₹1,841 Cr (20 Nov 2026)
P/E
35.46 (20 Nov 2026)
Revenue
₹137 Cr (September 2026 quarter)
Net profit
₹19 Cr (September 2026 quarter)
ROCE
19.2% (FY26)
ROE
18.8% (FY26)
Book value
₹394 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,807.90 / ₹990.10 (20 Nov 2026)
1-year return
1.4% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: BETA

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.